Navigation Links
Efavirenz-based initial therapies associated with better outcomes in HIV-infected adults
Date:10/14/2008

A study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that HIV-infected patients taking the antiretroviral drug efavirenz were more likely to adhere to treatment and less likely to experience virologic failure and death compared to patients taking nevirapine. Nevirapine is the most frequently prescribed drug for patients undergoing highly active antiretroviral therapy (HAART) for the treatment of HIV/AIDS in sub-Saharan Africa, where the study was conducted. The study is published in the October 18, 2008 issue of the journal AIDS.

"Our findings add to existing limited evidence that efavirenz-based therapies produce a more favorable virological and clinical outcome than nevirapine," says Jean Nachega, MD, PhD, MPH, lead author of the study and associate scientist with the Bloomberg School's Department of International Health. "Patients started on nevirapine had an increased risk of virologic failure and death, were significantly less likely than those started on efavirenz to achieve high treatment adherence."

Nachega, in collaboration with Gary Maartens, MD, FCP, professor of Medicine at University of Cape Town, and several other colleagues from the University of Cape Town in South Africa, examined the records of 2,817 HIV- infected adults currently enrolled in Aid for AIDS, a private-sector employer-subsidized disease management program in Africa. Participants were HAART nave adults who began nevirapine-based or efvirenz-based therapies between January 1998 and September 2004. Researchers determined how often patients requested reimbursement for their purchases of nevirapine- or efavirenz-based HAART to estimate adherence to their treatment regimens. They also evaluated patients CD4 counts, viral load changes and mortality, which are measurements that indicate how well a treatment is working. Program participants were in nine countries in Africa with the majority in South Africa.

Current World
'/>"/>

Contact: Tim Parsons
tmparson@jhsph.edu
410-955-7619
Johns Hopkins University Bloomberg School of Public Health
Source:Eurekalert

Page: 1 2

Related biology news :

1. Catcher Holdings Inc. Lands Contract for Initial Deployments at Nine Homeland Security and State Government Agencies
2. Carnegie Mellon scientists investigate initial molecular mechanism that triggers neuronal firing
3. Landmark study unlocks stem cell, DNA secrets to speed therapies
4. Argyrin: Natural substance raises hope for new cancer therapies
5. Newly identified role for power plants in human cells could lead to targeted therapies
6. 2 new therapies show promise for cancer patients
7. Challenges and promise of cell-based therapies
8. The construction of heart modelling leads path to new therapies
9. NCI renewal grant to develop new cancer therapies
10. Linchpin gene may be useful target for new breast cancer therapies
11. Low sperm count may be associated with prenatal testosterone excess
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... PULLMAN, Wash. Scientists at Washington State University ... specifically, Granny Smith apples may help prevent ... be the first to assess these compounds in ... in October,s print edition of the journal ... apples are a good source of these nondigestible ...
(Date:9/29/2014)... have found compounds that boost liver detoxification enzymes nearly ... placethe crushed seeds left after oil extraction from an ... compounds in Camelina sativa seed, also known ... phytochemicals that work together synergistically far better than they ... supplement because its bioactive ingredients increase the liver,s ability ...
(Date:9/29/2014)... is often deemed inaccessible or esoteric. Yet in the ... in our daily lives and a decisive role in ... behind the scenes. , UC Santa Barbara,s Paul Atzberger, ... assistant professor of mechanical engineering, often works in areas ... research published in the Proceedings of the National ...
Breaking Biology News(10 mins):An apple a day could keep obesity away 2New way to detox? 'Gold of Pleasure' oilseed boosts liver detoxification enzymes 2At the interface of math and science 2At the interface of math and science 3At the interface of math and science 4
... institutions, led by Stanford University and Brown University, have ... federal funding to learn both how the brain and ... can be done to encourage recovery from injury. ... developing the neurotechnology to ultimately enable an entirely new ...
... find answers about ovarian cancer, researchers now have something to ... been using the chicken as a model to study this ... with flaxseed decreases severity of ovarian cancer and increases survival ... of alpha-linolenic acid, one type of omega-3 fatty acid. Several ...
... normally infect rodents, but they are also infectious for ... symptoms in humans. Most importantly, these viruses have an ... any damage to healthy tissue. Therefore, scientists in the ... German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have been ...
Cached Biology News:New Stanford-led program aims to produce insights into brain injury, recovery 2New Stanford-led program aims to produce insights into brain injury, recovery 3Flaxseed-fed chickens shed light on ovarian cancer 2Flaxseed-fed chickens shed light on ovarian cancer 3Viruses against cancer 2Viruses against cancer 3
(Date:9/27/2014)... special section on single-photon detection, generation, and applications ... technologies with applications in areas as diverse as ... by providing more accurate measurement methods and new ... SPIE, the international society for optics and photonics, ... , The section appears in the August issue, ...
(Date:9/27/2014)... Texas at Dallas have created technology that could be ... sources or, more immediately, a smartphone that doesn,t die ... technology, published online in Nature Communications ... to control energy consumption inside transistors, which are at ... from the Erik Jonsson School of Engineering and Computer ...
(Date:9/26/2014)... , Sept. 26, 2014 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... the Company will hold its 2014 annual general meeting of shareholders ... Bank of China Tower, 1 Garden Road, Central, Hong ... 11, 2014 (8:00 a.m. U.S. Eastern Time on December 11, 2014). ...
(Date:9/26/2014)... Chester, NJ (PRWEB) September 26, 2014 ... of personal selling optimization technology and services for ... will present on Mobile Day at Digital Pharma ... October 21 at 10:30 a.m. , Steven Robinson, ... Director of Client Solutions, will be presenting “Test ...
Breaking Biology Technology:Single-photon detection, generation, and applications featured in Optical Engineering 2Single-photon detection, generation, and applications featured in Optical Engineering 3New UT Dallas technology may lead to prolonged power in mobile devices 2New UT Dallas technology may lead to prolonged power in mobile devices 3China Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 11, 2014 2Pursuit to Present at Digital Pharma East 2
... CHARENTON-LE-PONT, France, January 10 Essilor,of America, Essilor ... in the United States with the acquisition,of Interstate ... independent,laboratories. Interstate,s two laboratories in Mansfield, Ohio and,Indianapolis, ... The,company has full-year sales of US$26 million and ...
... of,Maryland, Baltimore (UMB) BioPark today announced that Gliknik ... in the BioInnovation,Center, located in UMB BioPark,s Building ... for autoimmune diseases,and cancer, the foundation of which ... Professor and Chairman of the Department of,Otorhinolarynogology, University ...
... 9 Burrill Merchant Banking acted as,exclusive financial ... partnering of bilastine with the Menarini Group (Italy). ... bilastine rights in Europe,and other regions to Menarini ... is a new highly selective H1 antihistamine for ...
Cached Biology Technology:University of Maryland, Baltimore BioPark Signs Gliknik Inc. as First Tenant in Its BioInnovation Center in Building Two 2Burrill Merchant Banking Advises Faes Farma on Bilastine Licensing Agreement 2